TheraRadar
← Back
Data updated: Jun 28, 2026

INDIVIOR

Big Pharma
Infectious DiseaseGastroenterology Execution: Excellent

INDIVIOR is a major pharmaceutical company focused on Infectious Disease, Gastroenterology. Key products include PERSERIS KIT.

1981
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules

INDIVIOR at a Glance

  • Strong track record with 100% execution quality across 38 trials
  • Fast trial execution (8 months median completion)

INDIVIOR's Key Drugs

INDIVIOR's core commercial portfolio centers on OPVEE, SUBLOCADE, spanning Infectious Disease and Gastroenterology — its most strategically important drugs approved in the last 15 years.

OPVEE
CNS

Opioid Overdose

Opioid receptors Approved 2023
SUBLOCADE
CNS

Opioid Use Disorder

Kappa-opioid receptor Approved 2017

INDIVIOR's Recent FDA Approvals

New NDA/BLA approvals for INDIVIOR over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INDIVIOR's Therapeutic Areas

INDIVIOR's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
0 drugs Phase 1: 1
Gastroenterology 50%
0 drugs Phase 1: 1

INDIVIOR's Top Competitors

INDIVIOR's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Infectious Disease, Gastroenterology
APOTHECON specialty
Infectious Disease, Gastroenterology
PF PRISM CV big-pharma
Infectious Disease, Gastroenterology
ASTELLAS specialty
Gastroenterology, Infectious Disease

INDIVIOR Pipeline Snapshot

INDIVIOR has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.

0
Phase 3
0
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OPVEE leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/5 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges